Download curriculum vitae - West Texas Retina

1
CURRICULUM VITAE
SUNIL S. PATEL M.D., Ph.D.
January 2012
Personal Information
Date of Birth:
Place of Birth:
Citizenship:
Age:
Home Address:
December 26, 1961
Palasar, India
USA
50
4224 South 20th Street
Abilene, Texas 79605
Home Telephone: (325) 793-2348
Family:
Wife: Laurie McAnally, MD (Family Practice)
Children: Rajal Patel
Jayna Patel
Vijay Patel
Business Address:
Business Telephone:
Cellular Telephone:
Fax number:
Ophthalmology Specialists of Texas, PA
5441 Health Center Drive
Abilene, Texas 79606
(325) 673-9806
(325) 660-8984
(325) 673-9809
Current Employment
Staff Vitreoretinal Surgeon
Managing Partner
Ophthalmology Specialists of Texas, PA
West Texas Retina Consultants
5441 Health Center Drive
Abilene, Texas 79606
(325) 673-9806
President
Integrated Clinical Research, LLC
Retina Research Institute of Texas
5441 Health Center Drive
Abilene, Texas 79606
(325) 690-4414
President
Abilene Surgery Center, LLC
5601 Health Center Drive
Abilene, Texas 79606
(325) 690-4466
Assistant Clinical Professor
Department of Ophthalmology
Texas Tech University School of Medicine
Lubbock, Texas
1
2
Previous Employment
Vitreoretinal Surgeon – Texas Retina Associates, PA (9/1997 to 9/2000), Dallas, Texas
Clinical Instructor – Doheny Eye Institute (7/1996 to 8/1997), University of Southern California, Los Angeles, California
Current or Previous Consulting Experience
Allergan
Alcon
EyeTech
Genentech
Ophthotech
Education
Bachelor of Science: University of California, Los Angeles (UCLA),
(Biochemistry)
Los Angeles, California (9/1979-6/1983)
Doctor of Philosophy:
University of Texas Southwestern Graduate School of Biomedical
Sciences, Dallas, Texas (6/1985-8/1989)
Doctor of Medicine:
(Immunology)
University of Texas Southwestern Medical School, Dallas, Texas (7/1983 - 5/1991)
Doctor of Philosophy Thesis
Advisor:
Date of defense:
Title:
Peter E. Lipsky, MD (6/1985-8/1989)
8/21/1989
Functional and phenotypic analysis of human T cell clones
Internship
Presbyterian Hospital of Dallas (7/1991-6/1992), Dallas, Texas.
Residency
Ophthalmology: Doheny Eye Institute-Los Angeles County Hospital (7/1992-6/1995), University of Southern California,
Los Angeles, California.
Fellowships
Surgical and medical vitreoretinal fellowship: Doheny Eye Institute-Los Angeles County Hospital (7/1/95 to 6/30/96),
University of Southern California, Los Angeles, California.
Uveitis fellowship: Doheny Eye Institute-Los Angeles County Hospital (7/1/96 to 7/31/97), University of Southern
California, Los Angeles, California.
2
3
Additional Training
Director of the vitreoretinal service at the USC-Los Angeles County Hospital (7/1/96 to 7/31/97).
Chief Resident at USC-Los Angeles County Hospital (7/1/96 to 6/30/97).
Collaborative Ocular Melanoma Study (COMS) certification for the diagnosis and management of choroidal melanoma
(7/1/96 to 8/1/97).
Ocular Oncology Training – Lynn Murphree at Doheny Eye Institute – USC School of Medicine (7/1/95 to 6/30/96)
SOCA (Study for Ocular Complications of AIDS) certification for the surgical placement of intraocular ganciclovir
implant.
Investigator Education for the Protection of Human Research Subjects (December 04, 2003)
Medical License
California: A051774
Texas: K4185
DEA: BP3670329
DPS: H0104495
Ophthalmology Board Certification
Diplomate of the American Board of Ophthalmology (10/1996)
Diplomate of the American Board of Ophthalmology (Renewal 10/2006)
Professional Societies
American Academy of Ophthalmology
American Society of Retinal Specialists
American Uveitis Society
American Medical Association
American Association of Immunologists
American Association for the Advancement of Science
Association for Research in Vision and Ophthalmology
International Society for Stem Cell Research
International Society for Cellular Therapy
Alpha Omega Alpha National Medical Honor Society
Phi Beta Kappa
Texas Ophthalmological Association
Undergraduate Awards, Honors, and Fellowships
Dean's Honor List at UCLA
Marilyn F. Lohr Memorial Physics Scholarship
Departmental Honors in the Department of Chemistry and Biochemistry at UCLA
Magna Cum Laude
Phi Beta Kappa National Honor Society
Golden Key Honor Society
UCLA Summer Research Fellowship
American Heart Association Research Fellowship
3
4
Graduate Awards, Honors, and Fellowships
Southwestern Medical Foundation Scholarship
Medical Scientist Training Program (National Institutes of Health) MD/PHD Predoctoral
Fellowship
Harold C. Simmons Research Fellowship
Alpha Omega Alpha Medial Honor Society
Post-Graduate Honors and Awards
Award for Excellence in Resident Training at the Doheny Eye Institute (1997)
American Academy of Ophthalmology Achievement Award (2009)
Texas Ophthalmological Association Council Member (2004-2010)
Texas Ophthalmological Association President Elect (2011)
Scientific Reviewer for Ophthalmology.
Research Interests
Cellular therapy in the management of retinal degenerative diseases.
Molecular mechanisms of immune regulation.
Applications of novel molecules in the management of retinal degenerative diseases.
Translational research – applications of regenerative medicine for retinal degenerative diseases.
New and innovative surgical therapies for management of retinal diseases.
Clinical Research Studies:
Alimera FAME C-01-11-008, “ An Open Label, Multi-center Extension Study of the Safety and Utility of the New
Inserter of Iluvien ® (Fluocinole Acetonide Intravitreal Insert) 0.19mg and the Safety of Iluvien in subjects with
Diabetic Macular Edema” (2011-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Allergan REACH AGN-150998, “Single and Repeat Dose of the Safety and Efficacy of AGN-150998 in patients
with Exudative Age-related Macular Degeneration” (2011-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Lpath NEXUS LT1009-Oph-003, “A phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study
Evaluating iSonep ™(Sonepcizumab [LT1009]) As either Monotherapy or adjunctive Therapy to Lucentis® or
Avastin® Alone for the treatment of subjects with choroidal Neovascularization Secondary to Age-Related Macular
Degeneration” (2011-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Regeneron Vista VGFT-OD-1009, “A Double-Masked, Randomized, Active-Controlled, Phase III Study of the
Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema”
(2011-Present)
Primary Investigator: Grant P. Janzen, M.D.
Sub-Investigator: S. Young Lee, M.D., Sunil S. Patel M.D., PhD
Allergan BDP 208397-001, “A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked,
Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME)
Associated with Retinal Vein Occlusion (RVO)” (2011-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
4
5
GlaskoSmithKline BAM114341, “A Phase II, Multi-centre, Randomized, Double-Masked, Placebo-Controlled,
Parallel-Group Study to investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of
GSK933776 in Adult Patients with Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration
(AMD)” (2011- Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Lpath Incorporated LT1009-OPH002, “A Phase 1B Multicenter, Open-Label and Randomized study of ISONEP
(Sonepcizumab/LT1009) administered as Intravenous Injections to subjects with PED Secondary to Exudative AgeRelated Macular Degeneration or Polypoidal Choroidal Vasculopathy.” (2011-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Genentech Shore FVF4967g, “A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment with
Intravitreal Ranibizumab in Subjects with Macular Edema Following Retinal Vein Occlusion.” (2011-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Genentech Mahalo CFD4870g, “A Phase Ib/II, Multicenter, Randomized, Single Masked, Sham-InjectionControlled study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered
monthly or Every other month to patients with Geographical Atrophy.” (2010-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub- Investigator: S.Young Lee, M.D., Grant P. Janzen, M.D.
Pfizer B1181002, “A Phase I, Double-masked, Placebo-controlled study evaluating the Safety and Tolerability,
Immunogenicity, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Dosages of RN6G (PF-04382923)
in subjects with Advanced Dry, Age-Related Macular Degeneration (AMD) including Geographical Atrophy”
(2010-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Allergan 190342-033D, “A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the biodegradation of the
Brimonidine Tartrate Posterior Segment Drug Delivery System.”
(2010-Present)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S.Young Lee, M.D., Grant P. Janzen, M.D.
DRCR Protocol N, “An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic
Retinopathy.” (2010-Current)
Primary Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Ophthotech OPH1001, “A PHASE 2, Randomized, Double-Masked, Controlled trial to establish the safety and efficacy
of intravitreous injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in combination with Lucentis® in subjects
with Neovascular Age-Related Macular Degeneration” (2010-Current)
Primary Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Regeneron VGFT-OD-0819, "A Randomized, Double Masked, Controlled Phase III Study of the
efficacy, safety and tolerability of repeated intravitreal administration of VEGF-Trap in subjects
with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). (2009-Present)
Primary Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
5
6
Genentech FVF4579g Harbor, “A Phase III, Double-Masked, Multicenter, Randomized, Active
Treatment-Controlled Study of the efficacy and safety of 0.5mg and 2.0 mg Ranibizumab
administered monthly or an as-needed basis (PRN) in patients with Subfoveal Neovascular Agerelated Macular Degeneration. (2009 – Present)
Primary Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Alcon C-08-36 (GATE), “The safety and efficacy of AL-8309B ophthalmic Solution for the
treatment of Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
(2009-Present)
Sub-Investigator: Sunil S. Patel M.D., Ph.D.
Primary Investigator: S. Young Lee, M.D.
Genentech FVF4168g RIDE, “A phase III, double-masked, multicenter, randomized, shamcontrolled study of the efficacy and safety of ranibizumab injection in subjects with clinically
significant macular edema with center involvement secondary to diabetes mellitus.” (2007-Current)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator, S. Young Lee, M.D., Grant P. Janzen, M.D.
DRCR Protocol O, “Comparison of Time Domain OCT and Spectral Domain OCT Retinal Thickness Measurement
in Diabetic Macular Edema.” (2009-2011)
Principal Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Ophthotech OPH3000ss, “A phase I ascending dose and parallel group trial to establish the safety, tolerability, and
pharmacokenetics profile of multiple intravitreous injections of Volociximab (α5β1 integrin antagonist as
monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular
Degeneration.” (2010-2011)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S.Young Lee, M.D., Grant P. Janzen, M.D.
Ophthotech OPH2001, “A Phase I study to establish the safety and tolerability of ARC1905 (ANTIC5 APTAMER) in subjects with Dry Age-Related Macular Degeneration.” (2009-2011)
Primary Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Victor Gonzales, M.D., PRESERVE, “Pegaptanib for Retinal Edema Secondary to
DiabeticVascular Disease.” (2010-2011)
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.
Allergan 190342-032D-01, “A Multicenter, Masked, Randomized, Sham-controlled, Paired-eyed
Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on
Retinal structure and Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery
System (Brimonidine Tartrate PS DDS) Applicator system in Patients with Geographical Atrophy
from Age-Related Macular Degeneration.” (2008-2011)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Regeneron VGFT-OD-0605, “A randomized, double masked, active controlled Phase III study of the
efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with
Neovascular Age-Related Macular Degeneration.” (2007-2011)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Alimera Sciences C01-05-001, “A randomized, double-masked, parallel group, multicenter, dosefinding comparison of the safety and efficacy of ASI-001A 0.5g/day and ASI-001B 0.2g/day
Fluocinolone Acetonide intravitreal inserts to sham injection in subjects with diabetic macular
edema.” (2006-2011)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee M.D.
6
7
Allergan 190342-031D-01, “A Multicenter, Masked, Randomized, Sham Controlled, Parallel-group, 3Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery
System (Brimonidine Tartrate PS DDS) Applicator System in improving Visual Function in patients with a previous
Rhegmatogenous Macular-Off Retinal Detachment.” (2009-2011)
Primary Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Alcon C-09-023 (Waltz), “A dose-escalated study of AL-39324 Suspension versus Lucentis® for the treatment of
Exudative Age Related Macular Degeneration.” (2009-2011)
Primary Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Regeneron VGFT-OD-0706, “A Double-Masked, Randomized, Controlled study of the safety and
efficacy, Tolerability and Biological effect of repeated Intravitreal Administration of VEGF-Trap in
patients with Diabetic Macular Edema (DME).” (2009-2010)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Genentech FVF3426g HORIZON, “An open-label, Multicenter extension study to evaluate the
safety and tolerability of Ranibizumab in subjects with Choroidal Neovascularization (CNV)
secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal
Vein Occlusion (RVO) who have completed a Genentech-sponsored Ranibizumab study.”
(2008-2010)
Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, M.D., Ph.D.
Ophthotech OPH3000, “A phase I ascending dose and parallel group trial to establish the safety,
tolerability and pharmacokenetics profile of multiple intravitreous injections of Volociximab (α5β1
integrin antagonist as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with
Neovascular Age-Related Macular Degeneration.” (2008-2010)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Ophthotech OPH2000, “A Phase 1, Ascending Dose and Parallel Group Trial to establish the
Safety, Tolerability and Pharmacokinetic Profile of Multiple Intravenous Injections of ARC1905
(ANTI-C5 APTAMER) Given either in combination therapy with multiple doses of Lucentis 0.5
mg/eye, or with one induction dose of Lucentis 0.5 mg/eye in subjects with Neovascular AgeRelated Macular Degeneration.” (2008-2010)
Primary Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D.
Allergan 206207-012-00, “A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks
additional follow-up) to assess the safety and efficacy of 700g Dexamethasone posterior segment drug delivery
system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser
photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema (DME).” (2007-2010)
Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: Sunil Patel, M.D., Ph.D.
Ophthotech OPH1000, “A Phase I, single ascending dose trail to establish the safety, tolerability
and pharmacokinetic profile of intravitreous injection of E10030 (Anti-PDGF Pegylated Aptamer)
monotherapy and of E10030 given in combination with Lucentis 0.5 Mg/eye in subjects with
Neovascular Age-Related Macular Degeneration.” (2007-2010)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Genentech FVF4165g BRAVO, “A phase III multicenter, randomized, sham injection-controlled
study of the efficacy and safety of ranibizumab injection compared with sham in subjects with
macular edema secondary to branch retinal vein occlusion.” (2007-2010)
Primary Investigator: S. Young Lee, M.D.
Sub-Investigator: Sunil S. Patel, M.D., Ph.D.
Genentech FVF4166g CRUISE, “A phase III, Multicenter, randomized, sham injection-controlled
study of the efficacy and safety of ranibizumab injection compared with sham in subjects with
macular edema secondary to central retinal vein occlusion.” (2007-2010)
Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, MD, PhD.
7
8
Allergan 206207-019, “A 26-week, Open Label study to assess the safety and efficacy of 700µg
Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy
to Lucentis® in the treatment of subjects with Choroidal Neovascularization Secondary to AgeRelated Macular Degeneration.” (2008-2009)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Allergan 206207-018, “A 26-week, Open-Label study to assess the safety and efficacy of 700µg
Dexamethasone Posterior Segment Drug Delivery System Applicator System in the treatment of
Vitrectomized subjects with Diabetic Macular Edema.” (2008-2009)
Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.
Allergan SIRIUS, “A 2-year, Multicenter, randomized, controlled, masked, dose-finding trial to
asses the safety and efficacy of multiple intravitreal injections of AGN 211745 in patients with
subfoveal choroidal neovascularization secondary to age-related macular degeneration.”
(2007-2009)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Allergan 206207-016, “A 6-Month, single- masked, multicenter, randomized, controlled study to assess the safety and
efficacy of 700g Dexamethasone posterior segment drug delivery system applicator system as adjunctive therapy to
Lucentis compared with Lucentis alone in the treatment of patients with Choroidal Neovascularization secondary to
Age-Related Macular Degeneration.” (2007-2009)
Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, M.D., Ph.D.
Jerini J0642701, “A Phase I open-label study to investigate the safety, tolerability and
pharmacokinetic profile of single and repeated doses of JSM6427 following administration by
intravitreal injection in patients with Neovascular Age-Related Macular Degeneration.” (20072009)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
OPKO Health ACU301C, “A Phase 3, Randomized, Double-masked, Parallel-Assignment Study of
Intravitreal Bevasiranib Sodium, Administered every 8 or 12 weeks as maintenance therapy
following three injections of Lucentis® Monotherapy every four weeks in patients with Exudative
Age-Related Macular Degeneration (AMD). “ (2007-2009)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Alcon C-06-30, “The Natural History of Geographical Atrophy Progression (GAP) Secondary to
Age-Related Macular Degeneration (AMD).” (2008-2009)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Allergan 206207-009-01, “A six-month, phase III, multicenter, masked randomized, sham-controlled
trial (with six0month open label extension) to assess the safety and efficacy of 700g and 350g
dexamethasone Posterior segment drug delivery system (DEX PS DDS) applicator system in the
treatment of patients with macular edema following central retinal vein occlusion or branch retinal
vein occlusion.” (2006-2009)
Primary Investigator: S. Young Lee M.D.
Sub-Investigator: Sunil Patel, M.D., Ph.D.
Eyetech 1023, “A phase IV, multi-center trial of maintenance intravitreous injections of
Macugen(Pegaptanib Sodium) given every 6 weeks for 48 weeks in subjects with subfoveal
neovascular age-related macular degeneration (AMD) initially treated with modality resulting in
maculopathy improvement.” (2006-2008)
Primary Investigator: Sunil S. Patel, M.D., PhD.
Sub-Investigator S. Young Lee, M.D.
ALCON C0459, “Anecortave Acetate 15mg administered every 3 months versus Anecortave Acetate
15mg administered every 6 months versus Anecortave Acetate 30mg administered every 6 months in
patients with exudative age-related macular degeneration.” (2005-2008)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
8
9
Alcon C-05-62, “A clinical evaluation of the safety and efficacy of preservative-free Triamcinolone
Acetonide sterile suspension for visualization during vitreoretinal surgery.” (2007)
Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, M.D., Ph.D.
ALCON C0418.“Clinical evaluation of the safety of Next Generation Ophthalmic Irrigating
Solution Compared to BSS Plus for use During Surgery for removal of epimacular membrane and
vitrectomy.” (2006-2007)
Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, M.D., Ph.D.
EYETECH EOP1012, “A phase 3B/4, randomized, active-controlled, double masked, single dummy,
multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous
injections of Macugen given every 6 weeks for up to 102 weeks plus sham Photodynamic Therapy to
Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal choroidal
neovascularization secondary to age-related macular degeneration.” (2005-2007)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
EYETECH EOP1013,” A phase 2/3, randomized, controlled, double-masked, multi-center,
comparative dose-finding trial in parallel groups, to compare the safety and efficacy of intravitreous
injections of 0.3, 0.03, 0.003mg Macugen, given as often as every 6 weeks for 3 years, to sham
injections, in subjects with Diabetic Macular Edema involving the center of the macula.”
(2005-2007)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
DRCR Protocol B, “ A randomized trial comparing intravitreal triamcinolone acetonide and
laser photocoagulation for DME.” (2004-2007)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Diabetic Retinopathy Clinical Research Network. “A Randomized Trial Comparing Intravitreal
Corticosteroids and Laser Photocoagulation for Diabetic Macular Edema.” (2004-2007)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
The Standard Care vs. Corticosteroid for Retina Vein Occlusion (SCORE) Study. “Two
Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injections of Triamcinolone
Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion
and One for Branch Retinal Vein Occlusion.” (2004-2007)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Eyetech EOP1011B. “A Phase II randomized, dose-ranging, double-masked, multi-center trial, in
parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of
pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due
to macular edema secondary to CRVO.” (2004-2005)
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
Genaera Corporation MSI-1256F-209. “A Phase 2, multi-center, Randomized, Masked, Controlled
Study of the MSI-1256F (Squalamine Lactate) for Treatment of Subfoveal Choroidal
Neovascularization Associated with Age-Related Macular Degeneration.” (2004-2005)
Primary Investigator: S. Young Lee, M.D.
Sub-Investigator: Sunil S. Patel, MD, PhD.
Alcon: Anecortave Acetate Risk-Reduction Trial (AART) C-02-60. “Multicenter, double-masked,
randomized, parallel groups clinical trial to demonstrate that Anecortave Acetate is safe and
effective versus sham in arresting the progression of non-exudative AMD in patients who are at-risk
for progressing to exudative AMD.”(2004-2008)
Primary investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
9
10
VAM study for management of Wet Age Related Macular Degeneration. Management of
predominantly classic subretinal neovascular membranes with Visudyne.(1999-2000).
Primary investigator: Sunil S. Patel, M.D., Ph.D.
Collaborative Ocular Melanoma Study (COMS) (1996-1997) at Doheny Eye Institute –
Management of Choroidal melanoma with radioactive plaque or enucleation. Certified as a plaguing
and enucleation surgeon.
MANUSCRIPTS (Authored)
Patel, S.S., D.L. Thiele, and P.E. Lipsky. 1987. Major histocompatibility complex-unrestricted cytotoxic activity of
human T cells. Analysis of precursor frequency and effector phenotype. J. Immunology. 139:3886.
Thiele D.L., S.S. Patel, and P.E. Lipsky. 1988. Anti-CD3 and phorbol myristate acetate regulation of MHC unrestricted T
cell cytotoxicity: Lack of a requirement for CD3/T cell receptor complex expression during tumor lysis. J. Immunology.
140:3253.
Davis, L.S., S.S. Patel, J.P. Atkinson, and P.E. Lipsky. 1988. Decay-accelerating factor functions as a signal transducing
molecule for human T cells. J. Immunology. 141:2246.
Patel, S.S., A.D. Duby, D.L. Thiele, and P.E. Lipsky.1988. Phenotypic and functional characterization of human T cell
clones. J. Immunology. 141:3726.
Geppert, T.D., M.C. Wacholtz, S.S. Patel, E. Lightfoot, and P.E. Lipsky. 1989. Activation of human T cell clones and
Jurkat cells by cross-linking class I major histocompatibility complex molecules. J. Immunol.142:3763.
Wacholtz, M.C., S.S. Patel, and P.E. Lipsky. 1989. Patterns of co-stimulation of T cell clones by cross-linking CD3,
CD4/CD8, and class I MHC molecules. J. Immunology. 142:4201.
Patel, S.S. 1989. Functional and phenotypic analysis of human T cell clones. University of Texas Southwestern Medical
School. Dissertation.
Wacholtz, M.C., S.S. Patel, and P.E. Lipsky. 1989. LFA-1 is a signaling molecule for human T lymphocytes. In Structure
and function of molecules involved in leukocyte adhesion.Eds. A.S. Rosenthal, T.A. Springer, D.C. Anderson, and R.
Rothlein. Springer-Verlag. p.254-264.
Wacholtz, M.C., S.S. Patel, and P.E. Lipsky. 1989. Leukocyte function-associated antigen 1 is an activation molecule for
human T cells. J. Exp. Med. 170:431.
Patel, S.S., M.C. Wacholtz, A.D. Duby, D.L.Thiele, and P.E. Lipsky. 1989. Analysis of the functional capabilities of
CD3+CD4-CD8- and CD3+CD4+CD8+ human T cell clones. J. Immunology. 143:1108.
Hirohata, S., S.S. Patel, and P.E. Lipsky. 1990. Regulation of human B cell responsiveness by CD8+ T cells: Differential
effects of stimulation with monoclonal antibodies to CD3 and pokeweed mitogen. Cell. Immunology. 127:35.
Patel, S.S., D.L. Thiele, and P.E. Lipsky. 1993. Stimulus-dependent modulation of human B cell function by T cell
clones. Cell. Immunology. 146:362.
Jou, J., S. S. Patel, C. Yo, A.A. Sadun. 1995. Orbital Coccidioidomycosis presenting as a lacrimal fossa mass. Brit J.
Ophthalmology. 79:1145.
Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P. Chong, and N.A. Rao. 1996. Cytomegalovirus papillitis in patients
with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Ophthalmology. 103:1476.
10
11
Marx, J.L., M.A. Kapusta, S.S. Patel, F. Walonker, N.A. Rao, and L.P. Chong. 1996. Use of the ganciclovir implant in the
treatment of recurrent CMV retinitis. Archives of Ophthalmology. 114:815.
Johnston, R.H., R.L. Nguyen, A. Jongsareejit, B.R. Lee, S. Patel, and L. Chong. 1999. Clinical Study of combined
penetrating keratoplasty, pars plana vitrectomy with temporary keratoprosthesis, and pars plana seton implant. Retina
19:116.
MANUSCRIPTS (Clinical Trials)
Collaborative Ocular Melanoma Study Group: The COMS randomized trial of Iodine 125 brachytherapy for choroidal
melanoma, III: Initial mortality findings. COMS Report No. 18. Archives of Ophthalmology. (2001)119:969.
Collaborative Ocular Melanoma Study Group: The COMS randomized trial of Iodine 125 brachytherapy for choroidal
melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. Archives of Ophthalmology.
(2001)119:951.
Collaborative Ocular Melanoma Study Group: Collaborative Ocular Melanoma Study (COMS).
Randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual Acuity after 3 years. COMS Report
No.16. Ophthalmology. (2001)108:348.
Collaborative Ocular Melanoma Study Group: Assessment of metastatic disease status at death in 435
patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS Report No. 15. Archives of
Ophthalmology. (2001)119:670.
SCORE Study Group, Bhavsar, AR, et al. The risk of Endophthalmitis following intravitreal triamcinolone injection in the
DRCRnet and SCORE clinical trials. Am J Ophthalmol. (2007) 144:454-456.
SCORE Research Group, Scott, IU, et al. A randomized trial comparing the efficacy and safety of
intravitreal triamcinolone with standard care to treat vision loss associated with macular edema
secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein
Occlusion (SCORE) Study Report 6. Arch Ophthalmol. (2009)127:1115-28.
SCORE Study Research Group, Ip, MS. et al. A randomized trial comparing the efficacy and safety of intravitreal
triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein
occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch
Ophthalmol.(2009) 127:1101-14.
SCORE Study Investigator Group, Scott, IU, et al. SCORE Study Report 7: Incidence of intravitreal silicone oil droplets
associated with staked-on vs. lure cone syringe design. Am J Ophthalmol. (2009)148:725-732.
DRCR:Sun JK, Aiello LP, Stockman M, Cavallerano JD, Kopple A, Eagan S, Qin H, Kollman C, Beck RW,
Glassman AR; Diabetic Retinopathy Clinical Research Network. Effects of dilation on Electronic-ETDRS Visual
Acuity in diabetic patients. Invest Ophthalmol Vis Sci. (2009) 50:1580-4.
DRCR:Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C,
Qin H; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and
reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal
bevacizumab for diabetic macular edema. Retina.2008 Jan;28(1):36-40.
DRCR:Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler
NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman
LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular
edema. Ophthalmology.2007 Oct;114(10):1860-7.
11
12
Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP,
Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a
randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic
macular edema. Arch Ophthalmol.2009 Mar;127(3):245-51.
Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal
triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.
Ophthalmology.2008 Sep;115(9):1447-9.e1-10.
DRCR: Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; Diabetic
Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and
focal/grid photocoagulation for diabetic macular edema: baseline features. Retina.2008 JulAug;28(7):919-30.
DRCR: Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris FL, Glassman AR, Ip MS,
Miller KM, for the Diabetic Retinopathy Clinical Research Network. Factors associated with
improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic
macular edema. Ophthalmology 2010 May;117:946-953.
Level Study Group, Friberg, TR, et al. Pegaptanib sodium as maintenance therapy in neovascular agerelated macular degeneration: the LEVEL study. 2010. Br J Ophthalmol.(in press)
ABSTRACTS
Kermani-Arab, V., S.S. Patel, J.L. Fahey, and A. Razzaque Ahmed. 1983. Interleukin 2 deficiency in
pemphigus. Clinical Research 31:578A.
Patel, S.S., D.L. Thiele, and P.E. Lipsky. 1987. Nonspecific cytotoxic potential of cloned human
Lymphocytes. Fed. Proc. 46:476 (#931).
Parkey, R.T., D.L. Thiele, S.S. Patel, and P.E. Lipsky. 1988. Lack of a requirement for CD3/T cell receptor
complex recognition in mediation of MHC-unrestricted cytotoxicity by activated T cells. FASEB J. 2:A463
(#975).
Patel, S.S., D.L. Thiele, and P.E. Lipsky. 1988. Human peripheral blood T cell clones exhibit multiple
functional activities. FASEB J. 2:A476 (#1047).
Ritter, A.R., L.S. Davis, S.S. Patel, J.P. Atkinson, and P.E. Lipsky. 1988. An antiserum to decayaccelerating factor (DAF) activates human T cells. FASEB J. 2:A871 (#3347).
Geppert, T.D., M.C. Wacholtz, S.S. Patel, E. Lightfoot, and P.E. Lipsky. 1988. T cell activation by crosslinking class I major histocompatibility complex (MHC) molecules. FASEB J. 2:A1655 (#7888).
Wacholtz, M.C., S.S. Patel, and P.E. Lipsky. 1988. Cross-linking class I major histocompatibility complex
(MHC) determinants stimulate human CD4+ and CD8+ T cell clones. FASEB J. 2:A1828 (#8897).
Thiele, D.L., S.S. Patel, and P.E. Lipsky. 1988. Anti-CD3 mediated regulation of MHC-unrestricted
cytotoxicity by activated T cells: Lack of role for CD3/T cell receptor complex in tumor lysis. Clinical
Research 36:449A.
Wacholtz, M.C., S.S. Patel, and P.E. Lipsky. 1989. LFA-1 as a signaling molecule. Clinical Research.
37:560A.
Patel, S.S., A.D. Duby, D.L. Thiele, and P.E. Lipsky. 1989. Functional characterization of human peripheral
blood CD3+CD4-CD8- and CD3+CD4+CD8+ T cell clones. FASEB J. 3:A515 (#1681).
12
13
Wacholtz, M.C., S.S. Patel, and P.E. Lipsky. 1989. LFA-1 (CD11a/CD18) as a signaling molecule in T cell
activation. FASEB J.3:A786 (#3349).
Kavanaugh, A., S.S. Patel, E. Lightfoot, P.E. Lipsky, and N. Oppenheimer-Marks. 1990. Delineation of the
capacity of CD18 deficient T cells to bind to and migrate through endothelial cells. FASEB J. 4:A2054
(#2092).
Patel, S.S., B.F. Jost, and G.E. Fish. 1992. Peripapillary choroidal neovascularization: laser treatment versus observation.
Amer. Acad. of Ophthalmology.
Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients
with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Amer. Acad. Of Ophthalmology.
Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients
with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Amer. Uveitis Society.
Patel, S.S., N. Ge, R. Varma, P. Chen, D.K. Heuer, P. Lee, M. Dacey, A. Phillips, and D. Minckler. 1996. Initial clinical
experience with the Ahmed glaucoma valve in the management of neovascular glaucoma. ARVO. S257 (#1173).
Ge, N., S. Patel, D. Heuer, D. Minckler, and R. Varma. 1996. Initial clinical experience with the Ahmed glaucoma valve
implant in the management of complicated glaucoma. ARVO.S258(#1179).
Kapusta, M., J.L. Marx, S.S. Patel, N.A. Rao, and L.P. Chong. 1996. The clinical outcome of high dose intravitreal
ganciclovir in progressive outer retinal necrosis. ARVO. S371(#1716).
Marx, J.L., M.A. Kapusta, S.S. Patel, F. Walonker, N.A. Rao, and L.P. Chong. 1996. The use of the ganciclovir implant
in the treatment of recurrent CMV retinitis. ARVO. S669 (#3072).
Johnston, R.H., P. Lee, S. Patel, M. Kapusta, D.A. Frambach, and L.P. Chong. 1997. Management of neovascular
glaucoma using combined pars plana vitrectomy and seton implant. ARVO.S769. (#3557).
Kapusta, M.A., R.L. Nguyen, R. Johnston, S. Patel, P. Lee, and L. Chong. 1997. Is a combined procedure of penetrating
keratoplasty, vitrectomy, and seton implant in the pars plana effective? ARVO. S666(#3123).
Patel, S.S. and R. Anand. 1998. A system for classifying diabetic tractional retinal detachments. AAO.
Patel, S.S., R. Anand, D. Callanan, and R. Leonard. 1999. Diabetic tractional retinal detachment: Anatomic and
functional variables important in visual prognosis. AAO.
Patel, S.S. and S.Y. Lee. NAION. AAO 2006
Patel, S.S., and CRVO study. ARVO2007
INVITED LECTURES
Patel, S.S., B.F. Jost, and G.E. Fish. 1992. Peripapillary choroidal neovascularization: laser treatment versus observation.
Amer. Acad. of Ophthalmology.
Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients
with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Amer. Acad. Of Ophthalmology.
13
14
Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients
with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Amer. Uveitis Society.
Patel, S.S. 1996. Ocular manifestations of the cytomegalovirus infection in patients with acquired immune deficiency
syndrome. Vanderbilt University Invited Lecture.
Patel, S.S. 1997. Ocular manifestations of the cytomegalovirus infection in patients with acquired immune deficiency
syndrome. University of Arkansas Invited Lecture.
Patel, S.S. 1998. Current management strategies for CMV retinitis. Southern Retinal Study Group. New Orleans, LA.
Patel, S.S. 1998. Evolution of macular hole surgery. Texas Tech University Alumni Lecture.
Patel, S.S. 1998. Evolution of macular hole surgery. Vanderbilt University Invited Lecture.
Patel, S.S. and R. Anand. 1998. A system for classifying diabetic tractional retinal detachments. Amer. Acad. of
Ophthalmology
Patel, SS and S Y. Lee. 2006. AAO. NAION.
PRESENTATIONS
Patel, S.S., B.F. Jost, and G.E. Fish. Peripapillary choroidal neovascularization: laser treatment versus observation.
Doheny Alumni Day 1993.
Patel, S.S., R. Kruger, and R. Green. Are two intraocular lenses better than one? Doheny Alumni Day 1994.
Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients
with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Doheny Alumni Day 1994.
Patel, S.S., N. Ge, R. Varma, P. Chen, D.K. Heuer, P. Lee, M. Dacey, A. Phillips, and D. Minckler. Initial clinical
experience with the Ahmed glaucoma valve in the management of neovascular glaucoma. Doheny Alumni Day 1996.
COURSES
Patel, S. S., R. Anand, D. Callanan, and W. Hutton. Surgical management of diabetic tractional retinal detachments.
AAO (1998).
Patel, S. S., R. Anand, D. Callanan, and W. Hutton. Surgical management of diabetic tractional retinal detachments.
AAO (1999).
Patel, S. S., R. Anand, D. Callanan, and R. Leonard. Surgical management of diabetic tractional retinal detachments.
AAO (2000).
14